Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.
暂无分享,去创建一个
[1] K. Pang,et al. Synthesis of singly 2H‐, 3H‐, and 14C‐ and doubly labeled acetaminophen, phenacetin, and p‐acetanisidine , 1982 .
[2] M Kieser,et al. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. , 1998, Pharmacopsychiatry.
[3] W. Müller,et al. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. , 1999, The Journal of pharmacology and experimental therapeutics.
[4] C. Erdelmeier. Hyperforin, Possibly the Major Non-Nitrogenous Secondary Metabolite of Hypericum perforatum L. , 1998, Pharmacopsychiatry.
[5] D. Bailey,et al. Grapefruit juice-drug interactions. , 1998, British journal of clinical pharmacology.
[6] D. Wortham,et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.
[7] C. Yoon,et al. Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. , 1998, Biochemical pharmacology.
[8] P. Schmidt,et al. Isolation, Purity Analysis and Stability of Hyperforin as a Standard Material from Hypericum perforatum L. , 1999, The Journal of pharmacy and pharmacology.
[9] F. Panzeri,et al. Identification by high-performance liquid chromatography–diode array detection–mass spectrometry and quantification by high-performance liquid chromatography–UV absorbance detection of active constituents of Hypericum perforatum , 1998 .
[10] P. Watkins,et al. 6′,7′‐Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P‐glycoprotein , 1999, Clinical pharmacology and therapeutics.
[11] A. Y. Lu,et al. Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.
[12] A. Nahrstedt,et al. Biologically Active and Other Chemical Constituents of the Herb of Hypericum perforatum L. , 1997, Pharmacopsychiatry.
[13] A. Alex,et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[14] S. Zhai,et al. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[15] S. Zhai,et al. COMPARATIVE INHIBITION OF HUMAN CYTOCHROMES P 450 1 A 1 AND 1 A 2 BY FLAVONOIDS , 1998 .
[16] F. Guengerich,et al. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.
[17] F. Guengerich,et al. Human cytochrome P-450 enzymes. , 1992, Life sciences.
[18] R. Tackett,et al. St. John's wort: a new alternative for depression? , 1999, International journal of clinical pharmacology and therapeutics.
[19] S. Chatterjee,et al. Oral Bioavailability of Hyperforin from Hypericum Extracts in Rats and Human Volunteers , 1998, Pharmacopsychiatry.
[20] I. Roots,et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) , 1999, Clinical pharmacology and therapeutics.
[21] S. Risch,et al. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. , 2000, Life sciences.
[22] W. Pryor. Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .
[23] J. Hölzl,et al. Biflavonoids in Hypericum perforatum 1; Part 1. Isolation of I3, II8-Biapigenin , 1987, Planta medica.